期刊文献+

药物基因组学在药动学研究中的应用 被引量:1

Application of Pharmacogenomics in Pharmacokinetic Study
下载PDF
导出
摘要 药物基因组学是一门充满活力并迅速发展的新兴学科,以探讨药物作用的遗传分布,确定药物作用靶点,提高药物效应及安全性为目标,研究影响药物分布、消除等个体差异的基因特性,以及基因变异所致的不同病人对药物的不同反应等。本文综述了药物基因组学在药动学研究中的进展情况,介绍和论述了药物基因组学的概念和研究内容;探讨了药物基因组学在药动学中的应用,药物代谢酶的多态性和药物转运体的多态性;并展望药物基因组学的应用前景。 Pharmacogenomics is a burgeoning discipline and is being developed rapidly. The aim of pharmacogenomics is to investigate the genetic distribution of the drugs, and to determine the targets of the drugs so as to ensure the optimal efficacy and safety in the clinical practices. It is also used to investigate individual gene characteristics which affect distribution and elimination, and patients' different response to the drug owing to gene variation is also studied. The advancement of pharmacogenomics in pharmacokinetic study was reviewed in this paper. And the polymorphisms of drug metabolizing enzymes and drug transporters were discussed as well. The prospect of its application was also forecast.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2005年第5期473-476,共4页 Journal of China Pharmaceutical University
关键词 药物基因组学 药动学 代谢酶 转运蛋白 Pharmacogenomics Pharmacokinetics Metabolizing enzyme Transporters
  • 相关文献

参考文献18

  • 1Norton RM.Clinical pharmacogenomics:application in pharmaceutical R&D[J].Drug Discov Today,2001,6(4):180 -185.
  • 2华允芬,明镇寰,张铭.药物基因组学研究进展[J].药学学报,2002,37(8):668-672. 被引量:13
  • 3Duggan DJ,Bittner M,Chen Y,et al.Expression profiling using cDNA microarrays[J].Nat Genet,1999,21(1 Suppl):10 -14.
  • 4Carulli GP,Artinger M,Swain PM,et al.High throughput analysis of differential gene expression[J].J Cell Biochem,1998,30 -31(Suppl):286 -296.
  • 5Lamba JK,Lin YS,Schuetz EG,et al. Genetic contribution to variable human CYP3A-mediated metabolism[J].Adv Drug Del Rev,2002,54(10):1 271 -1 294.
  • 6Draper AJ,Madan A,Parkinson A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes[J].Arch Biochem Biophys,1997,341(1):47 -61.
  • 7Nakajima M,Kwon JT,Tanaka N,et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans[J].Clin Pharmacol Ther,2001,69(1):72 -78.
  • 8Benowitz NL,Griffin C,Tyndale R. Deficient coxidation of nicotine continued[J].Clin Pharmacol Ther,2001,70(6):567.
  • 9Oscarson M,McLellan RA,Gullsten H,et al. Identification and characterization of novel polymorphisms in the CYP2A locus:implications for nicotine metabolism[J].FEBS Lett,1999,460(2):321 -327.
  • 10Chen GF,Tang,YM,Green B,et al. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method[J].Pharmacogenetics,1999,9(3):327 -332.

二级参考文献26

  • 1Vogel F. Moderne probleme der Humangenetik [J]. Ergeb Inn Med Kinderhilkd, 1959,12(52):125.
  • 2Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans dificient in debrisoquine metabolism [J]. Nature, 1988,331(6155):442-446.
  • 3Wieczorek SJ, Tsongalis GJ. Pharmacogenomics: will it change the field of medicine? [J] Clin Chim Acta, 2001,308(1-2):1-8.
  • 4Grant S. Pharmacogenetics and pharmacogenomics: tailored drug therapy for the 21st century [J]. Trends Pharmacol Sci, 2001,22(1):3-4.
  • 5Norton, Ronald M. Clinical pharmacogenomics: applications in pharmaceutical R&D [J]. Drug Discov Today, 2001,6(4):180-185.
  • 6Peet NP, Bey P. Pharmacogenomics: challenges and opportunities [J]. Drug Discov Today, 2001,6(10):495-498.
  • 7Bestenaves D, Thomas F. New advances in pharmaco-genomics [J]. Curr Opin Chem Biol, 2000,4(4):440-444.
  • 8Meyer U. Pharmacogenetics and adverse drug reactions [J]. Lancet, 2000,356(9242):1667-1671.
  • 9Brookes A. The essence of SNPs [J]. Gene, 1999,234(2):177-186.
  • 10Roses A. How will pharmacogenetics impact the future of research and development? [J] Drug Discov Today, 2001,6(2):59-60.

共引文献12

同被引文献18

  • 1牛春燕,罗金燕,王学勤,朱有玲.CYP2C19基因多态性对埃索美拉唑抑酸效应的影响[J].西安交通大学学报(医学版),2004,25(5):487-489. 被引量:13
  • 2姜英杰,李瑜元,聂玉强,王红,沙卫红.雷贝拉唑根除幽门螺杆菌疗效及其与CYP2C19基因多态性的关系[J].广州医学院学报,2004,32(3):22-25. 被引量:22
  • 3许振华,周宏灏.细胞色素氧化酶P4501A2与药物代谢[J].中国临床药理学杂志,1996,12(2):115-121. 被引量:22
  • 4Carulli GP,Artinger M,Swain PM,et al.High throughput analysis of differential gene expression[J].J Cell Biochem,1998,30(Suppl):286.
  • 5Yue Q,Jen JC,Thwe MM,et al.De novo mutation in CACNA1A Cause dacetazolamide responsive episodic at axia[J].Am J Med Genet,1998,77(4):298.
  • 6胡咏梅.CYP2C19基因多态性对雷贝拉唑、奥美拉唑药代动力学和药效学影响的研究.
  • 7许景峰 赵钢涛 边佳明 等.药物代谢CYP1家族相关基因的研究进展.中华医药杂志,2007,7(8):695-695.
  • 8Takahashi H,Echizen H.Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulantresponse to warfarin[J].Pharmacogenomics.2003,11(3):202.
  • 9Ito S,Ieiri I,Tanabe M,et al.Polymorphism of the ABC transporter genes,MDR1,MRP1 and MRP2 / cMOAT,in healthy Japanese subjects[J].Pharmacogenetics,2001,11(2):175.
  • 10Tokui T,Nakai D,Nakagomi R,et al.Pravastatin,an HMG-CoA reductase inhibitor,is transported by rat organic anion transporting polypeptide[J].Pharm Res,1999,16(6):904.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部